Recurrence rectal cancer in pelvis. SBRT offered

Appropriate management for recurrence of rectal cancer in the pelvis where stereotactic body radiotherapy (SBRT) is considered involves a highly individualized, multidisciplinary approach focusing on local control and potential curative intent when surgery is not feasible or declined.

SBRT may be considered as a curative-intent option primarily for patients with isolated pelvic lymph node recurrence or limited extraluminal recurrences who are not candidates for surgery or who decline operative management. In this setting, delivering a regimen such as 30 Gy in 5 fractions is typical, achieving favorable local control and acceptable toxicity, although the optimal dose and fractionation remain somewhat undefined Miller et al. 2026 Miller et al. 2026.

UK SABR Consortium guidance on pelvic SABR re-irradiation supports cautious dose escalation using an isotoxic approach up to 45 Gy in 5 fractions for locally recurrent rectal cancer, considering cumulative organ-at-risk constraints from previous radiotherapy Moreno-Olmedo et al. 2025. This approach may maximize tumor control without increasing toxicity, particularly when previous radiation fields overlap, and when higher doses are clinically justified to improve local control in non-surgical candidates Moreno-Olmedo et al. 2025.

Preoperative radiotherapy—potentially utilizing highly conformal techniques such as intensity-modulated radiation therapy (IMRT) or particle therapy—and concurrent or sequential systemic therapy are generally favored to facilitate tumor downsizing and improve the likelihood of achieving a margin-negative (R0) resection, which remains the strongest prognostic factor for long-term survival in pelvic recurrence Miller et al. 2026. Surgery with or without intraoperative radiation therapy (IORT) is the preferred curative approach if feasible, with SBRT reserved for inoperable or declined surgery cases Miller et al. 2026.

SBRT provides precise, high-dose radiation delivery ideally suited for controlling nodal or soft-tissue pelvic recurrences while sparing adjacent normal tissues, particularly in previously irradiated fields. Retrospective studies show median progression-free survival of about 12 months and overall survival around 28-39 months with low rates of high-grade toxicity, supporting its use as an ablative modality in selected patients Miller et al. 2026.

Overall, management proceeds as follows:

• Evaluate for candidacy for surgery aiming for R0 resection; if feasible, consider neoadjuvant RT and systemic therapy to improve resectability Miller et al. 2026.
• For patients not eligible for surgery, consider SBRT as a non-invasive ablative therapy, with treatment planning guided by cumulative prior radiotherapy doses and organ-at-risk constraints as per UK SABR national guidance Moreno-Olmedo et al. 2025.
• Employ isotoxic dose-escalation when possible to optimize tumor control without breaching normal tissue tolerances Moreno-Olmedo et al. 2025.
• Incorporate systemic therapy, based on molecular profile and prior treatments, concurrent with or sequential to radiation as appropriate Miller et al. 2026.
• Utilize advanced imaging modalities such as high-resolution MRI and PET/CT for precise disease mapping and treatment planning Miller et al. 2026.

This approach balances maximizing local control and quality of life while minimizing treatment-related toxicity, recognizing that prospective, high-level evidence is limited and ongoing audits and trials (e.g., TORCH-R) aim to refine these strategies Moreno-Olmedo et al. 2025 Miller et al. 2026.